On Tuesday, Medtronic Plc (NYSE: MDT) was 1.00% up from the session before settling in for the closing price of $95.58. A 52-week range for MDT has been $79.29 – $99.37.
Healthcare Sector giant saw their annual sales surged by 0.39% over the last five years. When this article was written, the company’s average yearly earnings per share was at 2.47%. With a float of $1.28 billion, this company’s outstanding shares have now reached $1.28 billion.
Medtronic Plc (MDT) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Medtronic Plc stocks. The insider ownership of Medtronic Plc is 0.07%, while institutional ownership is 86.23%. The most recent insider transaction that took place on Sep 03 ’25, was worth 788,048. In this transaction EVP & President Cardiovascular of this company sold 8,605 shares at a rate of $91.58, taking the stock ownership to the 35,615 shares. Before that another transaction happened on Sep 03 ’25, when Company’s Officer proposed sale 8,605 for $91.58, making the entire transaction worth $788,049.
Medtronic Plc (MDT) Earnings and Forecasts
Going through the last 3-months fiscal report unveiled on the 10/31/2024, it has been observed that the corporation posted 1.26 earnings per share (EPS) during the time that was better than consensus figure (set at 1.25) by 0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.35 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 2.47% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 5.95% during the next five years compared to 0.39% growth over the previous five years of trading.
Medtronic Plc (NYSE: MDT) Trading Performance Indicators
You can see what Medtronic Plc (MDT) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.50. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.62. Likewise, its price to free cash flow for the trailing twelve months is 23.35.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 3.62, a number that is poised to hit 1.31 in the next quarter and is forecasted to reach 6.08 in one year’s time.
